Cytopan

Quick links to important sections

Cytopan

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cytopan

Property Description
Active Ingredients Diclofenac Sodium and Misoprostol
Form Delayed-release tablets (Oral)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID) and Prostaglandin Analog Combination
General Purpose Symptom relief for chronic pain and inflammation with concurrent gastrointestinal protection
Origin Synthetic

Cytopan is a synthetic, fixed-dose combination product designed for oral administration, specifically categorized as a combination of a Nonsteroidal Anti-inflammatory Drug (NSAID) and a Prostaglandin Analog. The drug is supplied as delayed-release tablets, a specialized pharmaceutical preparation structured to control the timing of the release of its components in the digestive system. This dual classification immediately distinguishes Cytopan from single-ingredient NSAIDs, which typically lack the inherent protective mechanism. The overall classification reflects the pairing of anti-inflammatory properties with a concurrent protective mechanism, an approach clinically recognized for managing the gastrointestinal risks associated with long-term NSAID therapy.


Composition and The Rationale for the Dual Active Ingredients

Cytopan contains two primary active ingredients: Diclofenac Sodium and Misoprostol. The formulation's core composition involves the Diclofenac component, a phenylacetic acid derivative, which provides the therapeutic effect of reducing pain and inflammation, paired with the Misoprostol component, a synthetic Prostaglandin E₁ analog, which acts as a gastrointestinal mucosal protectant. This combination is strategically developed because the NSAID component works by inhibiting certain chemical pathways necessary for managing inflammation, but this action can disrupt the stomach's natural defenses. Therefore, the Misoprostol is included to replace the protective prostaglandins depleted by the Diclofenac, actively supporting the gastric lining by enhancing the mucous barrier and reducing acid secretion. The product is indicated for reducing the risk of developing ulcers caused by NSAIDs while treating symptoms like pain and stiffness. This combination is notably used in adult patients requiring continuous NSAID therapy for conditions involving chronic inflammation.

Regulatory References

  1. NIH DailyMed: Diclofenac Sodium and Misoprostol Full Prescribing Information
  2. FDA Drug Label Information

What side effects are possible with Cytopan?

Possible Side Effects and Safety Information

Cytopan (diclofenac sodium/misoprostol) carries Boxed Warnings regarding its serious safety risks, particularly concerning the cardiovascular and reproductive systems.

Serious Adverse Reactions and Restrictions

Cardiovascular Risks: The diclofenac component, a nonsteroidal anti-inflammatory drug (NSAID), is associated with an increased risk of serious cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke, which can be fatal. This risk may increase with the duration of use. The medication is contraindicated for use in the setting of coronary artery bypass graft (CABG) surgery.

Gastrointestinal (GI) Risks: NSAIDs increase the risk of serious GI adverse events, including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur without warning symptoms, and elderly patients are at greater risk.

Reproductive Risks (Misoprostol Component): Administration to women who are pregnant is absolutely contraindicated. Misoprostol can cause miscarriage, premature birth, birth defects, or uterine rupture. Women of childbearing potential must use effective contraception and have a negative pregnancy test prior to starting therapy.

Common Adverse Reactions

The most frequently reported side effects are gastrointestinal, generally involving the lower GI tract, and may include abdominal pain, diarrhea, dyspepsia (indigestion), nausea, and flatulence. Diarrhea and abdominal pain typically develop early in the course of therapy.

Other Safety Concerns

Additional documented adverse reactions across body systems include hepatotoxicity (liver damage), new-onset or worsening hypertension, renal toxicity (kidney damage), and rarely, serious skin reactions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The drug is contraindicated in patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.

Overdose and Emergency Response

Overdose and when to seek help

This information reflects the documented overdose profile for Cytopan (Diclofenac/Misoprostol) as stated in authoritative government regulatory sources.

Documented Overdose Manifestations

System Officially Documented Signs/Symptoms
Gastrointestinal Nausea, Vomiting, Epigastric Pain, Diarrhea, Gastrointestinal bleeding.
Central Nervous System Drowsiness, Lethargy, Sedation, Tremor, Convulsions.
Systemic/Cardio Fever, Dyspnea, Hypotension, Tachycardia.

Required Emergency Actions

An overdose can lead to potentially life-threatening outcomes, including Acute Renal Failure and Hepatic Dysfunction. Immediate medical attention is required for any suspected overdose. Regulatory guidance explicitly states that a Poison Control Center must be contacted immediately for management advice.

Management and Supportive Care

No specific antidote is known for Cytopan overdose. Management is restricted to symptomatic and supportive treatment. Procedures such as the administration of Activated Charcoal and the consideration of Gastric Lavage may be utilized if performed shortly after a significant ingestion, as documented in official prescribing information. Hospital monitoring and observation may be necessary, particularly for patients with signs of severe central nervous system or cardiovascular toxicity.

Therapeutic Uses of Cytopan

What Cytopan Treats: Main Uses and Benefits

The therapeutic domains of Cytopan are centered on providing symptomatic assistance during periods of heightened patient discomfort, as is relevant for therapeutic domains involving heightened symptomatic discomfort.

Cytopan is commonly used across conditions presenting with acute episodes or those characterized by periods of heightened symptoms. It is applied in clinical settings that involve acute or unstable symptom patterns, relevant when supportive symptom management is appropriate. This medicine may assist with addressing symptom clusters that can become intense or disruptive, such as those related to physical discomfort, localized tension, and functional strain.

In clinical scenarios, the medicine is often applied during phases of increased distress. The medicine provides support that helps ease the overall symptom burden, offering symptomatic relief that helps patients cope more steadily. It is often used when symptoms become temporarily overwhelming.

Applicable conditions may involve situations of episodic discomfort, fluctuating symptom patterns, and instances where symptoms create noticeable physiological strain.


Quick Fact: Support for Symptom Clusters The medicine is often applied when multiple symptoms occur together, creating noticeable interference with daily comfort.

Regulatory References

  1. NIH National Library of Medicine

Eligibility and Restrictions for Use

Who Can and Cannot Use Cytopan?

The population eligibility for Cytopan (Diclofenac Sodium and Misoprostol) is defined by strict regulatory criteria, primarily due to the potent nature of its components as documented by government health authorities. Use is generally restricted to adult patients requiring continuous NSAID therapy who are at high risk of developing NSAID-induced gastrointestinal ulcers.


Absolute Contraindications

Cytopan must not be used by several populations as dictated by official regulatory labeling:

  • Pregnant women or women who are attempting to become pregnant, due to the high risk of fetal harm (abortion, birth defects) associated with the Misoprostol component.
  • Patients with known hypersensitivity to Diclofenac, Misoprostol, or any NSAIDs (e.g., those with a history of asthma or allergic reactions to aspirin).
  • Patients with active gastrointestinal bleeding or peptic ulceration.
  • Patients undergoing (or immediately following) Coronary Artery Bypass Graft (CABG) surgery for peri-operative pain.

Population-Specific Restrictions

  • Pediatric Use: The medicine is not recommended for children and adolescents under 18 years of age as safety and efficacy have not been established.
  • Organ Impairment: Use is generally not recommended in patients with severe renal impairment or advanced hepatic impairment.
  • Older Adults: While permitted, use in older adults (65+) requires close regulatory caution due to an increased risk of severe gastrointestinal and renal adverse events.

What should I know about interactions with other medicines?

The official interaction profile for Cytopan is defined by the necessary management of risks associated with its dual-active composition. Co-administration with other systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or analgesic doses of Aspirin is formally restricted in regulatory labeling due to the elevated risk of serious gastrointestinal complications.

Pharmacodynamically, concurrent use with Anticoagulants (such as Warfarin), Oral Corticosteroids, or SSRIs may increase the documented risk of bleeding or ulceration. The Diclofenac component may reduce the antihypertensive and diuretic effects of medicinal products, including ACE inhibitors, ARBs, and certain diuretics.

Pharmacokinetic interactions involve the CYP2C9 enzyme system; inhibitors like Voriconazole or Fluconazole may enhance Diclofenac exposure, while inducers like Rifampin may reduce its systemic levels. The official labels also note that co-administration may increase the plasma concentrations of Lithium, Digoxin, and Methotrexate through reduced renal clearance. Co-administration with Cyclosporine or Tacrolimus may increase the risk of nephrotoxicity.

Specific timing rules are mandated for co-administration with Mifepristone and Pemetrexed in renally impaired patients. Magnesium-containing Antacids are officially restricted as they may exacerbate Misoprostol-related diarrhea. Furthermore, patients who are volume-depleted or have pre-existing renal impairment face an increased risk of acute renal failure when co-administered with ACE inhibitors or ARBs.

Mechanism of Action

Molecular Targeting: Inhibition of COX Enzymes

This primary mechanism involves Diclofenac, which acts as a non-selective inhibitor of the Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. By blocking the action of these enzymes, the drug prevents the conversion of arachidonic acid into prostaglandins and other eicosanoids, thereby diminishing the synthesis and release of inflammatory and nociceptive signaling molecules.


Gastric Defense via EP Receptor Agonism

The complementary mechanism is mediated by Misoprostol, a synthetic Prostaglandin E analog, which functions as an agonist for the EP3 and EP4 receptors located on the gastric mucosal cells. Activation of these receptors promotes the local secretion of mucus and bicarbonate while reducing gastric acid secretion, contributing to the physical stabilization of the mucosal barrier.


Mechanistic Compensation and Synergy

The combination is characterized by structural synergy where the two components operate in a biologically compensatory manner. Misoprostol's EP3 receptor agonism is specifically applied to override the negative physiological consequence of Diclofenac's COX inhibition—the depletion of endogenous prostaglandins—which results in the modulation of the inflammatory pathway concurrent with the maintenance of gastric PGE-mediated protection.

Dosage and Administration Information

The administration of Cytopan (Diclofenac Sodium and Misoprostol) is governed by specific guidelines that define its use as a continuous, long-term therapy. The medicine is prescribed for oral administration as a delayed-release tablet. To ensure the integrity of the delayed-release components, the tablets must be swallowed whole and must not be crushed, chewed, or broken under any circumstances. Proper administration also requires that the medicine be taken with food.

Standard adult dosing is structured to achieve maximal gastrointestinal mucosal protection. For conditions like osteoarthritis, the typical regimen involves taking one 50 mg/200 mcg tablet three times daily (TID). For rheumatoid arthritis, the regimen is one 50 mg/200 mcg tablet taken three or four times daily, with the total daily dose of the diclofenac component generally not exceeding 150 mg to 200 mg, depending on the indication. An alternative regimen using the 75 mg/200 mcg strength tablet twice daily (BID) is also established, though this frequency provides reduced misoprostol exposure for GI prophylaxis.

Usage principles emphasize utilizing the lowest effective dosage for the shortest duration consistent with patient goals. Specific population-based instructions state that while no dose adjustment is typically needed for older adults or those with mild-to-moderate hepatic or renal impairment, close monitoring is required. The safety and effectiveness of Cytopan have not been established for individuals under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cytopan


Research Evidence for Symptom Relief in Osteoarthritis

Research for Cytopan in Osteoarthritis (OA) was evaluated in short-term, double-blind Randomized Controlled Trials (RCTs). These studies examined the symptomatic changes, typically including adult patients whose symptoms required continuous use of anti-inflammatory medication. Researchers examined how symptoms changed over time, specifically measuring outcomes related to physical discomfort, stiffness, and functional ability using standardized patient-reported outcomes.

The findings describe patterns observed in the studies where measurements of change in OA-related symptoms were reported when the combination product was compared against a placebo. Research highlights changes measured during the study period which were observed in patterns similar to the symptomatic changes reported for the Diclofenac component when studied alone. The research also concurrently monitored physiological strain on the digestive system, reporting that a lower incidence of endoscopically-diagnosed ulcers was associated with the combination group.


Research Evidence for Ulcer Risk Reduction

The combination product was studied for how it relates to reducing the risk of upper gastrointestinal ulcers in high-risk patients. The evidence is derived from Randomized, Double-blind Studies focused on adult patients with OA or RA at high risk of developing ulcers due to continuous NSAID use. Research examined the incidence of gastrointestinal events as the core outcome, specifically monitoring the incidence of endoscopically-confirmed gastric ulcers.

Multiple studies reported a statistically consistent pattern suggesting an association with a lower measured rate of gastric ulcers in the high-risk patient cohort when receiving the combination product compared to those receiving the NSAID component alone. Research provides insight into short-term changes, but also indicates that the protective effect appears to be dose-dependent on the Misoprostol component.


What is Still Uncertain About Cytopan's Research Landscape

Several research limitations are noted. Follow-up durations were limited in most key studies (typically 6 to 12 weeks), meaning long-term effects are not fully established for symptom management. Comparative evidence is lacking for direct head-to-head trials against other fixed-dose NSAID/gastroprotective combination products. Additionally, results apply only to the populations studied, meaning the applicability of findings to patients with multiple, serious existing health conditions (comorbidities) is not fully characterized by the current evidence base.

Key Studies & References

  1. Diclofenac/misoprostol: novel findings and their clinical potential (Review of mechanisms and clinical data)
  2. Diclofenac sodium with misoprostol Public Summary Document (PSD) - TGA/PBAC Regulatory Review

Frequently Asked Questions (FAQ)

Common questions about Cytopan (FAQ)

Q: How quickly should I feel an effect after starting Cytopan?

Cytopan contains diclofenac, an anti-inflammatory component that typically reaches its maximum concentration in the blood within hours after administration. However, official clinical studies for chronic conditions like arthritis measure the full symptomatic benefit and change over a period of weeks. Official product information suggests that the time to observe therapeutic changes may vary among individuals.

Q: Does Cytopan have any known interactions with herbal supplements?

Regulatory documents list specific drug-to-drug interactions, but do not provide a comprehensive list for all herbal supplements. Since Cytopan is known to affect bleeding risk and liver enzymes, it is noted that caution is generally advised regarding the use of herbal products.

Q: What are the known drug interactions between Cytopan and cholesterol medicines?

While the drug label does not specifically name statins, a common class of cholesterol medicine, official warnings highlight the risk of hepatotoxicity (liver damage) associated with NSAIDs like diclofenac. Official warnings highlight that the risks of liver or kidney problems are noted when assessing concurrent medication use.

Q: Why do some people experience headaches when they take Cytopan?

Official product information reports that headaches are an adverse event that was observed in clinical trials. This is listed under the general category of effects on the central and peripheral nervous system.

Q: Can Cytopan cause changes in mood or sleep patterns?

Yes, official labeling reports that adverse psychiatric and nervous system effects have been observed in some patients. These include symptoms such as anxiety, depression, irritability, and sleep disturbances like insomnia or drowsiness.

Q: Is it necessary to avoid alcohol completely while on Cytopan?

Regulatory warnings indicate that consuming alcohol is a risk factor that can increase the chance of developing serious gastrointestinal adverse events, such as bleeding and ulcers, while taking Cytopan.

Q: Can I use over-the-counter cough and cold remedies with Cytopan?

It is important to note that caution is advised regarding the use of cough and cold remedies. The official label strictly advises against co-administration with other systemic NSAIDs or analgesic doses of aspirin, which are common ingredients in many over-the-counter cold medicines.

Q: Can taking Cytopan make you feel tired or drowsy?

Official regulatory labeling reports that drowsiness, fatigue (feeling tired), and asthenia (a lack of energy or weakness) are adverse events that have occurred in patients taking Cytopan.

Q: Is it normal to have slight nausea when first starting Cytopan?

Nausea is listed as a frequently reported gastrointestinal side effect in official product information. Digestive side effects, such as diarrhea and abdominal pain, often develop early in the course of therapy.

Q: Does Cytopan affect the ability to drive or operate machinery?

Since adverse effects like dizziness and drowsiness have been reported, official guidance suggests that individuals should exercise caution regarding activities such as operating machinery or driving.

Q: Can I take Cytopan if I have a history of liver problems?

The drug carries a warning for Hepatotoxicity (liver damage). Official product information states that use in patients with advanced hepatic impairment is generally not recommended, and liver function should be monitored.

Q: Does Cytopan affect blood pressure or heart rate?

Official warnings state that the NSAID component can lead to the new onset or worsening of pre-existing hypertension (high blood pressure). The Boxed Warning on cardiovascular risk underscores the importance of monitoring heart health during treatment.

Q: Is it true that Cytopan is absorbed better at a certain time of day?

Official regulatory guidance requires that Cytopan be taken with food to aid administration and absorption. However, the product information does not specify that one time of day (such as morning versus evening) is superior for absorption.

Q: What if I'm already taking multiple prescriptions, is Cytopan still an option?

Official labeling highlights potential interactions with many other medications, including blood thinners, certain blood pressure medicines, and psychiatric drugs. A comprehensive review of all current prescriptions is required to manage known risks of bleeding, increased drug exposure, or kidney toxicity.

Q: Is Cytopan a type of antibiotic or something else?

No, Cytopan is not an antibiotic. According to official classification, it is a combination drug consisting of a Nonsteroidal Anti-inflammatory Drug (NSAID) and a Prostaglandin Analog. It is used to relieve symptoms of chronic inflammatory conditions while protecting the stomach.

Q: Can Cytopan cause long-term problems if taken for a while?

Official Boxed Warnings note that the serious cardiovascular and gastrointestinal risks associated with the NSAID component may increase with the duration of use. Most clinical studies had limited follow-up, meaning the long-term safety is not fully established by the core evidence.

Q: Is it safe to drink coffee while taking Cytopan?

The misoprostol component of Cytopan is known to inhibit acid secretion in response to various stimuli, including coffee. Generally, no clinically significant interaction with the drug's intended action has been reported for common coffee intake.

Q: Is Cytopan suitable for people with pre-existing kidney issues?

Official warnings advise that patients with severe renal (kidney) impairment should avoid using Cytopan. Furthermore, all patients with pre-existing kidney issues should be closely monitored during treatment for the potential risk of renal toxicity.

Q: What makes Cytopan different from other similar medicines?

Cytopan is specifically designed as a fixed-dose combination product containing two active ingredients: the NSAID diclofenac for anti-inflammatory effects and misoprostol, a prostaglandin analog, for gastrointestinal protection. This dual composition distinguishes it from single-ingredient NSAIDs.

Q: Is there a generic version of Cytopan available?

Yes, the product, which contains the active ingredients Diclofenac Sodium and Misoprostol Delayed-Release Tablets, is officially listed with multiple generic packagers and distributors.

Q: How long does Cytopan stay in your system after stopping it?

Pharmacokinetic data from official sources indicate the components are cleared relatively quickly. The diclofenac component has a short half-life of 1.2 to 2 hours, and the active misoprostol metabolite has a very short terminal half-life, meaning it is rapidly eliminated from the bloodstream.

Q: What should I look out for as a sign that Cytopan is working?

Cytopan is indicated for the relief of the signs and symptoms of conditions like osteoarthritis and rheumatoid arthritis. Improvement in pain, stiffness, or function are outcomes that may be observed, consistent with the drug's intended purpose.

Q: Is Cytopan considered a high-risk medication?

Official labeling indicates that the drug is associated with serious safety risks. This is evidenced by the inclusion of Boxed Warnings regarding cardiovascular thrombotic events, severe gastrointestinal adverse events, and the contraindication for use during pregnancy.

Q: Can you be allergic to Cytopan even if you're not allergic to other drugs?

Official product information states that the medicine is contraindicated if you have a known hypersensitivity to the components of Cytopan or other prostaglandin medicines. This is separate from, though it includes, those with known allergies to aspirin or other NSAIDs.

Q: How reliable are the long-term safety studies for Cytopan?

Regulatory documents indicate that the follow-up durations for many key clinical studies were limited (typically 6 to 12 weeks). This means that the findings may not fully characterize the safety profile for chronic symptom management beyond the established study duration.

Q: Is Cytopan safe to use for women who are planning pregnancy?

Official labeling indicates that the drug is absolutely contraindicated in women who are pregnant or are attempting to become pregnant, due to the high risk of fetal harm. Women of childbearing potential must use effective contraception before and throughout treatment.

Q: What are the signs of a serious, but rare, allergic reaction to Cytopan?

Official warnings address serious, life-threatening skin reactions. Reported signs include a severe skin rash or blistering, often accompanied by a fever, and swelling of the face or throat, which are severe allergic symptoms.

Q: Do patients typically gain or lose weight when taking Cytopan?

Official warnings note that unusual weight gain or swelling of the hands, arms, feet, or legs is a symptom that should be monitored, as fluid retention can be an indicator of kidney problems or heart failure associated with NSAIDs.

Q: Is Cytopan used for any conditions besides its main approved use?

The drug's regulatory indications cover the treatment of signs and symptoms of osteoarthritis or rheumatoid arthritis in adult patients who are also at high risk of developing NSAID-induced ulcers.

How should Cytopan be stored and disposed of?

How to Store and Dispose of Cytopan?

Cytopan (diclofenac sodium/misoprostol) storage and disposal instructions are based on official regulatory guidelines to maintain drug stability and ensure safety.


Official Storage Requirements

Storage Component Requirement
Temperature Store at 20 C to 25 C (68 F to 77 F). Permitted excursions are 15 C to 30 C (59 F to 86 F).
Protection Protect from moisture. Keep the medication in its original blister packaging.
Access Keep Cytopan securely stored and out of the reach of children.

Official Disposal Instructions

Unused or expired Cytopan must be disposed of according to established government guidelines. Follow instructions for drug take-back programs that are available in your area. If a take-back program is not available, specific household disposal rules should be followed as documented in official materials; the medication should not be flushed down a toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cytopan found in:

A-Z Index: